Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
Screen a stock
TERMINAL
NV

NVSStockNovartis AG - ADR

New York Stock Exchange · Healthcare · CH

$150.47 last close 2026-11-20
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment NVS's does — no target price to set, unlike a price alert.

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-07-31
Assessed 2026-07-31
2 of 2 pass our own screen — 5 of 7 could not be computed
HTR non-permissible income <0.01%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 1 bearish
43
of 100
Setup confidence — system conviction, not win probabilityD

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

MEAN_REVERSION
Entry
$155.21
Stop
$154.72
Target
$160.08
Risk : Reward 9.9R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 100.0% aligned
VWAPPrice below VWAP ($155.31)
VolumeRelative volume 4.9× the 20-day average
Momentum10-day rate of change -6.5%
Overall readNEUTRAL — No Edge

Novartis AG - ADR (NVS) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-07-31). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Wall Street consensus
HOLD
34 analysts
Institutional own.
7.3%
of shares
Momentum (10d)
-6.5%
rate of change
SMC grade
D · 43
100.0% aligned
<0.01%
Non-permissible income — HTR, from filings (2025-12-31)
D · 43
SMC grade — 100.0% timeframe alignment
-6.5%
Rate of change (10d)
HOLD
Wall Street consensus (34)
7.3%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to NVS’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

  • Nov 21, 2026 Not rated → Compliantour daily record began reading this page's own headline on this date; the page's status did not change here
  • Nov 17, 2026 Tracking began Nothing before this date is on record.

Read once a day from the status this page publishes, last on Nov 21, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2025-12-31. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $229.7B as of 2026-09-09. At the 2026-11-20 close it is about $253.4B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 11.3% (12.5% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 4.6% (5.0% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 12.51% 30.00% Pass(17.5pp buffer)
Interest-bearing investments 5.02% 30.00% Pass(25.0pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Usmani Pass 5 of 5 ratios pass
RatioValueThresholdResult
Interest-bearing debt 25.89% 33.00% Pass(7.1pp buffer)
Interest-bearing investments 10.39% 33.00% Pass(22.6pp buffer)
Non-liquid assets 89.61% at least 20.00% Pass(69.6pp above the floor)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Net liquid assets per share $-15.7B under mkt cap $229.7B Pass
MSCI Unverified⚠️ a figure this standard needs was not available, so it could not be scored — the rows below show what was and was not computed 3 of 4 computed, all pass
RatioValueThresholdResult
Interest-bearing debt 25.89% 33.33% Pass(7.4pp buffer)
Cash + interest-bearing securities 10.39% 33.33% Pass(22.9pp buffer)
Accounts receivable
receivables not reported
not available 33.33% Unverified
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
FTSE Unverified⚠️ a figure this standard needs was not available, so it could not be scored — the rows below show what was and was not computed 3 of 4 computed, all pass
RatioValueThresholdResult
Interest-bearing debt 25.89% 33.33% Pass(7.4pp buffer)
Cash + interest-bearing securities 10.39% 33.33% Pass(22.9pp buffer)
Accounts receivable
receivables not reported
not available 50.00% Unverified
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Dow Jones Islamic Market Unverified⚠️ a figure this standard needs was not available, so it could not be scored — the rows below show what was and was not computed 3 of 4 computed, all pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 14.28% 33.00% Pass(18.7pp buffer)
Cash + interest-bearing securities 5.73% 33.00% Pass(27.3pp buffer)
Accounts receivable
receivables not reported
not available 33.00% Unverified
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
S&P Shariah Unverified⚠️ a figure this standard needs was not available, so it could not be scored — the rows below show what was and was not computed 3 of 4 computed, all pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 15.28% 33.00% Pass(17.7pp buffer)
Cash + interest-bearing securities 6.13% 49.00% Pass(42.9pp buffer)
Accounts receivable
receivables not reported
not available 49.00% Unverified
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
MSCI M-Series Unverified⚠️ a figure this standard needs was not available, so it could not be scored — the rows below show what was and was not computed 3 of 4 computed, all pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 15.28% 33.33% Pass(18.0pp buffer)
Cash + interest-bearing securities 6.13% 33.33% Pass(27.2pp buffer)
Accounts receivable
receivables not reported
not available 49.00% Unverified
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 5.0pts
Usmani (% of total assets)non permissible income ratio 5.0pts
Usmani (% of total assets)debt ratio 7.1pts

The numbers the ratios are built from

Read from NVS's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $56.7B 2025-12-31 yahoo:annualTotalRevenue
Interest-bearing debtShort and long-term borrowings $28.7B 2025-12-31 Borrowings
Cash and interest-bearing securitiesCash, equivalents and marketable securities $11.5B 2025-12-31 CashAndCashEquivalents, ShorttermDepositsNotClassifiedAsCashEquivalents
Total assetsBalance sheet total $110.9B 2025-12-31 Assets
Market capDenominator for AAOIFI $229.7B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $227.2B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $244.0B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $0 2025-12-31 no interest-income tag reported in 3+ years (treated as $0)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2025-12-31. Income statement as of 2025-12-31. Screened 2026-09-09.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$110.9B
    Assets · balance sheet as of 2025-12-31
  • Interest-bearing debt$28.7B
    Borrowings · balance sheet as of 2025-12-31
  • Cash and interest-bearing securities$11.5B
    CashAndCashEquivalents, ShorttermDepositsNotClassifiedAsCashEquivalents · balance sheet as of 2025-12-31
  • Revenue$56.7B
    yahoo:annualTotalRevenue · income statement as of 2025-12-31
  • Interest income (non-permissible)$0
    no interest-income tag reported in 3+ years (treated as $0) · income statement as of 2025-12-31
  • Market cap$229.7B
    Market-data quote at screen time, 2026-09-09 · not a filing figure, so no link

What changed, and when

Verdict history for NVS. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for NVS has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 2 pass and 0 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2025-12-31; market cap as stored on 2026-09-09.

The ratios that move with the share price

AAOIFI's debt ratio (12.5% against a 30% line) would only fail if the market cap fell by 58%, to $95.8B. At the 2026-11-20 close it would read 11.3%.

AAOIFI's investments ratio (5.0% against a 30% line) would only fail if the market cap fell by 83%, to $38.4B. At the 2026-11-20 close it would read 4.6%.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Drug Manufacturers - General listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
LLYLilly(Eli) & Co $1.2T —
JNJJohnson & Johnson $658.0B —
ABBVAbbvie Inc $467.4B —
MRKMerck & Co Inc $371.7B —
AZNAstrazeneca plc - ADR $252.0B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold NVS

9 of the 247 funds whose filed holdings we currently hold own NVS shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns NVS.

Shariah funds
FundNVS in fundFund compliant by weight
UMMA Wahed Dow Jones Islamic World ETF 2.60% 89%
SPWO SP Funds S&P World (ex-US) ETF 1.44% 87%
Other funds
FundNVS in fundFund compliant by weight
GUBGX Victory RS International Fund 2.98% 46%
CAXAX Catalyst/MAP Global Equity Fund 2.58% 47%
MRSHX MFS Research International Fund Also MRSKX, MRSRX 2.06% 51%
DBEU Xtrackers MSCI Europe Hedged Equity ETF 1.91% 44%
MSACX Passport Overseas Equity Portfolio 1.67% 62%
CDHIX Calvert International Responsible Index Fund 0.95% 57%
HDVTX Hartford International Equity Fund Also HDVVX 0.22% 45%

Sorted by NVS’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names NVS once, so a bond is not counted as the shares; 2 more funds name NVS in a way we cannot separate from its bonds, and are not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding NVS
InvestorFirmPositionWeightAs of
Ken Fisher Fisher Asset Management $2,390M 0.7% 2026-09-30
Ken Griffin Citadel Advisors $471M 0.1% 2026-09-30
Dodge & Cox Dodge & Cox $105M 0.1% 2026-09-30
Peter Brown Renaissance Technologies $94M 0.1% 2026-09-30
Israel Englander Millennium Management $78M 0.0% 2026-09-30
Steven Cohen Point72 Asset Management $46M 0.1% 2026-09-30
Saturna Capital Amana Mutual Funds Trust $44M 0.5% 2026-09-30
Jeremy Grantham GMO $40M 0.1% 2026-09-30
Paul Tudor Jones Tudor Investment Corp $29M 0.0% 2026-09-30
Charles Brandes Brandes Investment Partners $27M 0.2% 2026-09-30
Larry Robbins Glenview Capital Management $12M 0.2% 2026-09-30
Tweedy, Browne Tweedy, Browne Company $10M 0.8% 2026-09-30
David Shaw D. E. Shaw & Co. $10M 0.0% 2026-09-30
Peter Schiff Euro Pacific Asset Management $6M 0.5% 2026-09-30
Azzad Asset Management Azzad Asset Management $4M 0.4% 2026-09-30
Lee Ainslie Maverick Capital $3M 0.0% 2026-09-30
Sallie Krawcheck Ellevest $2M 0.2% 2026-09-30
Kahn Brothers Kahn Brothers Group $2M 0.3% 2026-09-30
Joel Greenblatt Gotham Asset Management $1M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

164.98154.44143.89133.35122.802025-11-242026-05-272026-11-20

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
147.79
S2
149.26
S1
150.24
PIVOT
151.71
R1
152.69
R2
154.16
R3
155.14

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
139.64 – 151.78
±4.17% from 145.71, made 2026-09-29 · resolves 2026-10-06
SELL
from 19 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
2 buy · 0 neutral · 10 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)38.50NEUTRAL
Stochastic %K (14)1.46BUY
CCI (20)-172.07BUY
Williams %R (14)-98.54BUY
MACD (12,26,9)-1.72SELL
ROC (10)-7.43SELL
Momentum (10)-12.08SELL
EMA (10)156.57SELL
SMA (10)158.43SELL
EMA (20)156.80SELL
SMA (20)159.16SELL
EMA (30)155.70SELL
SMA (30)156.08SELL
EMA (50)154.01SELL
SMA (50)150.46BUY
EMA (100)152.17SELL
SMA (100)152.30SELL
EMA (200)149.50BUY
SMA (200)152.14SELL

About Novartis AG - ADR

Healthcare · Drug Manufacturers - General

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

novartis.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-11-19

MEAN REVERSION
Type
155.21
Entry
154.72
Stop
160.08
Target
LOSS
Outcome · exit 151.21 (-2.58%)

Stop 154.72 Now 150.47 Target 160.08

Verdict

⚪ NEUTRAL — No Edge

Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.

Scores: 2 bullish / 1 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 64
⏰ 4H BEARISH 49
🕐 1H BEARISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-6.5%
Rate of change (10d)
4.9×
Volume vs its 20-day average
0.81
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-17 · Asset managers net 895049 (-19081)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.